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We examined familial aggregation and risk of age-related macular degeneration in the Utah population using a population-based
case-control study. Over one million unique patient records were searched within the University of Utah Health Sciences Center and
the Utah Population Database (UPDB), identifying 4764 patients with AMD. Specialized kinship analysis software was used to test
for familial aggregation of disease, estimate the magnitude of familial risks, and identify families at high risk for disease. The popula-
tion-attributable risk (PAR) for AMD was calculated to be 0.34. Recurrence risks in relatives indicate increased relative risks in siblings
(2.95), ﬁrst cousins (1.29), second cousins (1.13), and parents (5.66) of aﬀected cases. There were 16 extended large families with AMD
identiﬁed for potential use in genetic studies. Each family had ﬁve or more living aﬀected members. The familial aggregation of AMD
shown in this study exempliﬁes the merit of the UPDB and supports recent research demonstrating signiﬁcant genetic contribution to
disease development and progression.
 2008 Published by Elsevier Ltd.
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Age-related macular degeneration (AMD) is the most
common cause of vision loss in elderly individuals in the
developed world (Hageman et al., 2001; Kaplan, Leibole,0042-6989/$ - see front matter  2008 Published by Elsevier Ltd.
doi:10.1016/j.visres.2007.11.013
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1 These authors contributed equally to this work.Tezel, & Ferguson, 1999; Klein, Klein, & Linton, 1992;
Krzystolik et al., 2002; Okamoto et al., 1997; Penfold, Kil-
lingsworth, & Sarks, 1985; Vingerling et al., 1995). Early
AMD is characterized by drusen deposition and hyper-
or hypo-pigmentation of the retinal pigment epithelium
(RPE) without vision loss (Fig. 1B). Advanced AMD can
be classiﬁed into two categories: geographic atrophy
(GA), characterized by atrophy of the RPE (Fig. 1C),
and choroidal neovascularization (CNV, wet AMD,
Fig. 1D). Estimates suggest that 1.75 million people in
L. Luo et al. / Vision Research 48 (2008) 494–500 495the United States suﬀer from advanced AMD and 8 million
people are aﬀected by early AMD, putting them at risk to
develop advanced disease (Friedman et al., 2004).
AMD is a multi-factorial disease involving the interplay
of genes and environmental factors. Various twin and sib
studies have demonstrated a high concordance of AMD
development (Meyers, Greene, & Gutman, 1995; Seddon,
Cote, Page, Aggen, &Neale, 2005), and previous population
studies have also highlighted the heritability of AMD (Hei-
ba, Elston, Klein, & Klein, 1994; Klaver et al., 1998; Klein,
Klein, Lee, Moore, & Danforth, 2001; Seddon, Ajani, &
Mitchell, 1997). The most convincing evidence for genetic
contribution in AMD is the identiﬁcation of major disease
susceptibility alleles on chromosomes 1q32 (CFH region)
and 10q26 (LOC387715/HTRA1 region). Speciﬁcally, the
risk of developing AMD is associated with the C allele of
the Y402H variation in CFH (Edwards et al., 2005; Hag-
eman et al., 2005; Haines et al., 2005; Klein et al., 2005; Zare-
parsi et al., 2005). In addition, a single nucleotide
polymorphism, rs11200638, located in the promoter region
of theHTRA1 gene, confers a signiﬁcant increase in the risk
of developing advancedAMD (Cameron et al., 2007;Dewan
et al., 2006; Yang et al., 2006). Other research has focused on
investigating environmental risk factors that may contributeFig. 1. Fundus photography of normal control (A) and AMD cases (B–D) ide
drusen (black arrow); C, geographic atrophy (white arrow) and soft drusen (b
(white arrow).to AMD, such as smoking, which has an associated odds
ratio ranging from 1.8 to 3 (Smith et al., 2001).
However, the exact contribution and relative impor-
tance of genetic and environmental factors in AMD path-
ogenesis remains uncertain (van Leeuwen, Klaver,
Vingerling, Hofman, & de Jong, 2003). Few studies have
established familial patterns of susceptibility, which may
prove important in elucidating the relationship between
genetic and environmental components in AMD. Large
AMD pedigrees may complement current and future
genetic association studies by revealing the heritability of
AMD disease-contributing genes. These pedigrees may
help demonstrate disease causation related to speciﬁc poly-
morphisms. The Utah Population Database (UPDB) can
help identify large pedigrees of AMD families to poten-
tially be utilized in various studies such as linkage analysis
and mode of genetic transmission.
The appeal of studying AMD in the Utah population is
also magniﬁed when assessing the state’s demographic data.
During the second half of the 19th century, the average num-
ber of children per couple was 7.7 for once-married women
(Bean,Mineau, & Anderton, 1990). Utah residents continue
to have large families, reporting an average family size of
3.57, as compared to 3.14 for the U.S. overall (www.gover-ntiﬁed in Utah Population Database. A, normal control; B, conﬂuent soft
lack arrow); D, choroidal neovascularization (black arrow) and atrophy
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tors are less prevalent in the state as compared to the rest
of the U.S. population. For example, the CDC Behavioral
Risk Factor Surveillance System reports that Utah has one
of the lowest alcohol consumption rates in the nation and
the lowest tobacco consumption rate at 9.8% (http://
www.cdc.gov/brfss/). Large family size, minimization of
environmental factors shown to be associated with AMD
such as smoking (Klein, Klein, & Moss, 1998) and alcohol
consumption (Klein, Klein, Tomany, &Moss, 2002), as well
as the copious data available from the UPDB makes the
Utah community a unique and useful group to study.
This study attempts to demonstrate the familial aggrega-
tion of AMD using the UPDB, a University of Utah
research resource that represents over 6 million individuals
and covers a period from the late 1700s to the present. In
this study, we identiﬁed extensive AMD pedigrees in Utah
and calculated AMD risk in parents, siblings, ﬁrst cousins,
and second cousins, which enabled us to evaluate the pop-
ulation-attributable risk (PAR) in this unique population.2. Methods
2.1. Study design
This is a population-based cross-sectional and case-control study using
data from the UPDB. The UPDB includes data from the Family History
Library maintained by the Church of Jesus Christ of Latter-day Saints
(LDS), vital records from the Utah State Department of Health, and other
statewide data sets (http://www.hci.utah.edu/groups/ppr/data.html). The
resource includes family history data on approximately 4 million individ-
uals, representing pedigrees that span up to 11 generations. The majority
of families living in Utah are represented in this database with a special
emphasis on genealogy records of the founders of Utah and their descen-
dants (Skolnick, Bean, & Dintelman, 1979).
Beginning in 2003, a link between medical information contained in
the University of Utah Health Sciences Center (UUHSC) and family his-
tory information in the UPDB was established to facilitate studies of the
familiality of a broad range of diseases. The UUHSC contains more than
1.5 million patient demographic records and includes medical information
on both in-patient and out-patient records. Over one million (74%)
patients have been matched to a ‘‘person record’’ in the UPDB. The exten-
sive family histories available in the UPDB, combined with information
from UUHSC medical records and statewide vital records, allow for the
identiﬁcation of large pedigrees and calculation of population-based risks
of diseases such as AMD. The following results emphasize the valuable
resources available for identifying AMD genes for this study.
This study has been approved by the University of Utah IRB and the
Utah Research for Genetic and Epidemiological Research (RGE). The
RGE is the administrative body for the UPDB (Wylie & Mineau, 2003).2.2. AMD cases
UUHSC hospital and clinic records were searched to identify patients
with varying severities of AMD, classiﬁed by ICD9 codes. ICD9 codes
362.50, 362.51 and362.52were used to code for senilemacular degeneration,
unspeciﬁed, nonexudative senilemacular degeneration, and exudative senile
macular degeneration, respectively. A total of 4764 patients were identiﬁed.
Only patientswith at least oneparent or one child in theUPDBwere used for
further familial statistical assessments. Most of the family information was
drawn from the genealogy records of Utah founder families indicating that,there is a limited number of subjects with relatives in the database. From
these results, 2772 records (58%) had suﬃcient family information in the
UPDB to be included in the PAR and relative risk (RR) analyses.
2.3. Population controls
After identifying AMD cases, controls were selected from the linked
UUHSC-UPDB cohort. Only controls with family information recorded
in the UPDB were used. Controls were also matched to cases by gender
and birth year ±2.5 years, presence in the linked UPDB-UUHSC set
(1,072,860 patients), and absence of AMD diagnosis. One control was
picked per case, and controls were not reused.
2.4. Statistical analyses2.4.1. Familial standardized incidence ratio (FSIR)
The FSIR (Kerber, 1995) permits quantiﬁcation of an individual’s
familial risk of disease, taking into account the number of biological rela-
tives, degree of relatedness to the proband, and person-time at risk among
family members. FSIR is calculated by tabulating the observed and
expected numbers of cases of disease among all of an individual’s relatives
and weighting the contribution of each relative by the probability that the
relative shares an allele with the subject by common descent. Boucher and
Kerber (2001) describe an empirical Bayes adjustment for measurement
error.
2.4.2. Population-attributable risk
PAR was calculated using a conditional logistic regression method as
described by Bruzzi (Bruzzi, Green, Byar, Brinton, & Schairer, 1985).
First, a conditional logistic regression model is used to predict relative risk
as a function of FSIR. From this model, individual probabilities of causa-
tion (PAC) for each case are computed where PAC = (RR  1)/RR,
where RR is the relative risk estimated from the model for the observed
level of FSIR. The PAR is calculated as the mean PAC across all the cases.
2.4.3. Relative risks
RRs for parents, siblings, and ﬁrst and second cousins of the 2772
cases were also calculated using unconditional logistic regression, follow-
ing the method described by Bai, Sherman, Khoury, and Flanders (2000).
2.4.4. Pedigree p-values
The probability of a family having some observed number of cases (x)
under the null hypothesis of no familial disease aggregation is the Poisson
probability of X > x given an expected number, l.
3. Results
The identiﬁed population of AMD cases and matched
controls were utilized to calculate various risks of disease
development, demonstrating familial risk of AMD. These
risks include the proportion of disease in the population
attributable to familial factors, or PAR, as well as the
recurrent risks among family members related to patients
who have a diagnosis of AMD. RRs were broken down
to speciﬁc familial relation to the aﬀected cases.
Using data from conditional logistic regression compu-
tations the raw PAR for AMD was calculated to be 0.22
(95% CI 0.16–0.27), and the adjusted PAR was 0.34 (95%
CI 0.25–0.41). Increased RR was found in siblings, ﬁrst
cousins, second cousins, and parents of aﬀected cases, as
displayed in Table 1 (with 95% conﬁdence intervals).
Identiﬁcation of 16 large pedigrees containing at least
ﬁve or more aﬀected family members, having a p value
Table 1
Number of cases, controls, and relative risk of individuals with diﬀerent relationships to probands for AMD
Relationship Cases (n = 2772) Controls (n = 2772) Relative risk (95% CI) p value
Aﬀected Unaﬀected Aﬀected Unaﬀected
Parent 70(2.22%) 3088(97.78%) 10(0.41%) 2408(99.59%) 5.66(2.89–11.08) 4.33 · 1007
Sibling 199(9.69%) 1855(90.31%) 60(3.48%) 1664(96.52%) 2.95(2.19–3.97) 9.40 · 1013
First cousin 349(3.60%) 9332(96.40%) 260(2.78%) 9093(97.22%) 1.29(1.10–1.52) .002011
Second cousin 1687(3.12%) 52464(96.88%) 1410(2.68%) 51282(97.32%) 1.13(1.05–1.22) .000689
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ial aggregation of AMD in the Utah population. The kin-
ship analysis software provided a founder Person ID for
each family, number of descendents, observed number of
aﬀected individuals, expected number of aﬀected individu-
als, FSIR, and standard error. Data such as birth year,
death year, and gender on pedigree founders and all
aﬀected cases was given for each familial cluster. Findings
were reviewed with careful manual analysis of each aﬀected
case identiﬁed in the clusters. Large pedigrees were drawn
out using Peddraw software, and the results are shown in
Fig. 2.
There were 28 families identiﬁed having ﬁve or more liv-
ing aﬀected members within each family. For each of these
families the p value under the null hypothesis of no familial
disease aggregation is .05 or less and the FSIR value is 1.5
or higher. The family members within these pedigrees were
compared. They reduced to 16 extended large families. In
some instances more than one founder was identiﬁed for
the same group of cases. This is annotated in Table 2 with
the cluster number followed by a letter corresponding toFig. 2. Pedigree (cluster #6) identiﬁed from Utah Poputhe diﬀerent founder. The number of descendents in each
family ranged between 38 and 8231 members, and FSIRs
for each family ranged from 1.90 to 214, as shown in Table
2. The median number of descendents in each pedigree was
1365 and the median FSIR was 3.95, demonstrating a
strong familial aggregation of AMD in Utah families. Thus
the linked UPDB-UUHSC records and kinship analysis
software provides the basis to identify and recruit extended
families with clustering of AMD.
4. Discussion
AMD risk can be signiﬁcantly attributed to genetic fac-
tors, and this study conﬁrms that AMD aggregates in Utah
families. The range in FSIR further demonstrates the
multi-factorial nature of AMD. Environmental data such
as diet and smoking history is not available directly from
the UPDB. However, this data could be collected during
patient interviews and may prove to further enhance sin-
gle-family studies. The adjusted PAR for AMD using the
UPDB was found to be 34%. This is consistent with popu-lation Database containing 16 living AMD cases.
Table 2
Sixteen families identiﬁed from Utah Population Database
Cluster Descendants Observed Expected FSIR p value
1a 1238 5 1.2519 3.9939 .0092
1b 2044 7 2.1032 3.3283 .0059
2 1725 5 1.6904 2.9578 .029
3a 468 8 0.4015 19.9239 0
3b 182 7 0.2077 33.7044 0
3c 107 7 0.0889 78.7024 0
3d 373 7 0.4678 14.9622 0
3e 38 7 0.0326 214.4589 0
4 3670 6 2.4634 2.4357 .0396
5 2934 7 3.1483 2.2235 .0415
6a 2911 6 1.7249 3.4784 .0086
6b 8231 11 5.8038 1.8953 .035
7a 1327 5 1.2754 3.9203 .0099
7b 1404 5 1.4638 3.4157 .0169
8 1181 5 0.8854 5.6474 .0022
9 1677 6 1.6042 3.7402 .0061
10a 1685 6 1.427 4.2046 .0035
10b 1998 7 1.6882 4.1463 .0018
11a 935 5 0.7177 6.9663 .0009
11b 390 5 0.445 11.2355 .0001
11c 790 6 0.7226 8.3029 .0001
11d 380 6 0.4147 14.4698 0
12 2212 7 2.0202 3.465 .0048
13 1271 5 1.2963 3.8573 .0105
14 3234 9 2.6379 3.4118 .0016
15 2358 5 1.9638 2.546 .0494
16a 4177 8 2.4293 3.2931 .0036
16b 605 5 0.5624 8.8907 .0003
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attributable risk of anywhere from 42% to 76% (Grizzard,
Arnett, & Haag, 2003; Hammond et al., 2002; Klaver et al.,
1998; Klein, Mauldin, & Stoumbos, 1994; Meyers, 1994;
Seddon et al., 1997, 2005). Our estimates may be somewhat
conservative as AMD cases may be underdiagnosed due to
the assumption of unaﬀected status when there was no
AMD diagnosis given in the UUHSC system, as the
UUHSC is only one of many medical care options in the
Utah state. Another possible limitation of our study is that
data was only available on 58% of those with AMD. The
UPDB is currently working with other health care provid-
ers throughout the state to incorporate their medical
records into this database. This would help further delin-
eate AMD status in our population. This is an ongoing
study, and we plan to re-assess this population periodically
in the future in order to incorporate new diagnostic infor-
mation. A future direction of this study will include more
speciﬁc ICD9 code stratiﬁcation to assess only advanced
AMD and correlate this risk of vision loss from AMD.
While several population-based studies have demon-
strated familial aggregation of AMD (Heiba et al., 1994;
Klaver et al., 1998; Klein et al., 2001; Seddon et al.,
1997), this is the ﬁrst study to show relative risks of second
cousins. Studies of second cousins may provide a more
impartial estimate of familial aggregation of AMD by fur-
ther reducing various environmental bias such as diet,
smoking, and alcohol consumption. A particularly interest-
ing observation in this study was the relative risk of secondcousins (1.13) when compared with the percentage of
shared alleles (2%). Additionally, in today’s age of avail-
able information and better understanding of genetic inﬂu-
ence on common diseases, questions regarding risk and
prevention of disease are often posed in the clinical setting.
The recent discovery of the CFH and HTRA1 alleles asso-
ciated with AMD has appeared in mainstream news
sources, and often patients inquire as to their odds of devel-
oping AMD based on both family history and genetic test-
ing availability. Common disease predisposition genes
identiﬁed in Utah are represented similarly in other U.S.
and international studies in terms of frequency and pene-
trance. Relative risks for cancer and other diseases calcu-
lated for this population are comparable to published
estimates for other populations (Goldgar, Easton, Can-
non-Albright, & Skolnick, 1994). The Utah population is
biologically representative of a broad spectrum of the Cau-
casian U.S. population and is genetically similar to other
Northern European-derived populations. The Utah popu-
lation has a low consanguinity rate that is very similar to
that of the U.S. population due to a large founding popu-
lation and high rates of immigration from a diverse group
of outside populations (Jorde, 1989; McLellan, Jorde, &
Skolnick, 1984). Therefore, we feel that the relative risk cal-
culations based on UPDB data can reasonably be extended
to other communities.
The extensive AMD pedigrees identiﬁed in this study
can aid in further understanding the genetics and patho-
genesis of AMD. Blood samples and phenotypic data
have been collected on several members of these large
pedigrees and the value of these pedigrees may become
even more apparent with recent genetic discoveries. The
possibility of underlying genetic heterogeneity for disease
often lessens enthusiasm for linkage studies. In the face
of genetic heterogeneity represented by multiple genes
for a single disorder, the importance of extended pedi-
grees with large numbers of aﬀected patients becomes
apparent. A small number of large, independently infor-
mative pedigrees, such as the ones identiﬁed in this study,
may also help to deﬁne new linked regions for AMD and
provide more clarity and narrower regions in currently
identiﬁed loci. The approach to localization and isolation
of predisposition genes using a population-based geneal-
ogy and a population-based registry of aﬀected individu-
als has been successful in Utah in the localization and/
or cloning of many disease genes in diseases such as p16
in melanoma (Berthelemy-Okazaki et al., 2005; Kamb
et al., 1994) and the two hereditary breast cancer genes
BRCA1 (Miki et al., 1994) and BRCA2 (Tavtigian
et al., 1996, 2001; Wooster et al., 1994).
The combination of PAR ﬁndings, RR calculations, and
cluster analysis demonstrates familial aggregation of AMD
in the Utah population. The UPDB is a powerful tool to
identify familial risk and large pedigrees with several
aﬀected members of AMD, and future use of the database
may aid in ﬁndings in other common eye diseases such as
glaucoma and diabetic retinopathy. These pedigrees and
L. Luo et al. / Vision Research 48 (2008) 494–500 499risk assessments of the Utah population have broad clinical
applications and may help play an important role in under-
standing the pathogenesis and progression of AMD.
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